

Oxlumo Order Form (lumasiran)

FAX TO: 817-472-7213

PATIENT INFORMATION				
Patient Name:				_
Primary Language:Al	lergies:			
Patient Preferred Location:				
<icd 10="" code="" required=""></icd>	DIAGNOSIS & C	LINICAL INFOR	MATION	
<u>ICD 10 Code</u> E72.53 Primary Hyperoxaluria				
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS:</u> Include baseline CMP.				
PRESCRIPTION				
OXLUMO (lumasiran)				
If patient is naive to therapy, select appropriate option or both loading and maintenance dosing				
Loading Dose (SELECT ONE) Body Weight < 10kg: Administer 6 mg/kg by subcutaneous injection once monthly for 3 doses Body Weight 10kg to < 20kg: Administer 6 mg/kg by subcutaneous injection once monthly for 3 doses Body Weight > 20kg: Administer 3 mg/kg by subcutaneous injection once monthly for 3 doses				
Maintenance Dose* (SELECT ONE) Body Weight < 10kg: Administer 3 mg/kg by subcutaneous injection once monthly, beginning 1 month after last loading dose Body Weight 10kg to < 20kg: Administer 6 mg/kg by subcutaneous injection once every 3 months, beginning 1 month after last loading dose Body Weight > 20kg: Administer 3 mg/kg by subcutaneous injection once every 3 months, beginning 1 month after last loading dose				
* Supply maintenance dosing for 1 year unless otherwise noted here:				
Is the patient on any other disease modify If yes, please note therapy and last dose:	ving therapy?	es No		
Post Treatment Observations: The patient is observed for 30 minutes following the first administration. Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol. Comments:				
PRESCRIBER INFORMATION				
Prescriber Name: Signature:				
Date: NPI #:				
Supervising Physician:		•		
Address:				, , , ,
Contact Name:	•			·